Skip to content

Effects of Different Inhaled Oxygen Concentrations Combined with Flurbiprofen Ester Pretreatment on Pulmonary Function in Patients Undergoing Thoracoscopic Lobectomy: A 2×2 Factorial Design Randomized Controlled Trial

Effects of Different Inhaled Oxygen Concentrations Combined with Flurbiprofen Ester Pretreatment on Pulmonary Function in Patients Undergoing Thoracoscopic Lobectomy: A 2×2 Factorial Design Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110166
Enrollment
Unknown
Registered
2025-10-09
Start date
2025-10-13
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Group A:Fluoropyrofen ester 1 mg/kg (IV injection 15 minutes prior to anesthesia induction) + FiO2 60% (from initiation of single-lung ventilation until completion of surgery)
Group B:Flurbiprofen ester 1 mg/kg (IV injection 15 minutes prior to anesthesia induction) + FiO280% (from initiation of single-lung
Group C:Normal saline (IV infusion 15 minutes prior to induction of anesthesia) + FiO2 60% (from initiation of single-lung ventilation
Group D:Normal saline (IV infusion 15 minutes prior to induction of anesthesia) + FiO2 80% (from initiation of single-lung ventilation

Sponsors

The Fourth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective unilateral thoracoscopic lobectomy with single-lung ventilation using a occluder (either left or right lobe), of any gender, aged 18–64 years, with a BMI of 18.5–27.9 kg/m^2, and ASA physical status classification of I–III. Preoperative pulmonary function: FEV1/FVC >= 70%.

Exclusion criteria

Exclusion criteria: 1. Exclusion Criteria: History of severe cardiovascular or respiratory disease prior to surgery; history of abuse of anesthetic analgesics; history of psychiatric or neurological disorders; patients with peptic ulcers; patients with severe hepatic, renal, or hematologic dysfunction; patients with severe heart failure or hypertension; patients with a history of allergy to dexmedetomidine, flurbiprofen esters, aspirin-induced asthma or history thereof, current use of levofloxacin, lomefloxacin, or norfloxacin, nonsteroidal anti-inflammatory drug (NSAID) use within 24 hours prior to surgery, contraindications to flurbiprofen ester use, lactation, or contraindications to occluder use.

Design outcomes

Primary

MeasureTime frame
Oxygenation Index (OI);

Secondary

MeasureTime frame
Iactate level;Airway peak pressure, Ppeak;plateau airway pressure;Pulmonary dynamic compliance, Cdyn;Ratio of void cavity to tidal volume;

Countries

China

Contacts

Public ContactHuanshuang Pei

The Fourth Hospital of Hebei Medical University

huanshuangpei@163.com+86 139 3012 5450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026